BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

Reuters12-17 19:45

BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

** Brokerage RBC Capital Markets says biotech sector has strongly rebounded since April 2025, helped by good clinical data and successful new drug launches, creating more profitable, mature mid-cap names

** Brokerage says M&A is booming (about $101B in 2025, over double compared with 2024), and big pharma still needs to buy growth, so deal activity should stay strong into early 2026

** Believes the funding environment has improved: secondary offerings and private financing are up, and 2025 IPOs have performed well, suggesting the IPO window should reopen in 2026

** Policy and pricing fears (IRA, MFN, tariffs, inflation) are proving less damaging than initially feared, though regulatory volatility will continue, says brokerage

** RBC says after the big rally, valuations are less cheap and many hot areas are crowded, so investors must be more selective

** Brokerage sees Kymera Therapeutics KYMR.O, Apogee Therapeutics APOG.O, Xenon Pharmaceuticals XENE.O and Ascendis Pharma A71.F as potential takeout targets

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592994926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592994926","market":"us","top_or_hot":-1,"title":"BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026</title></head><body><p>** Brokerage RBC Capital Markets says biotech sector has strongly rebounded since April 2025, helped by good clinical data and successful new drug launches, creating more profitable, mature mid-cap names</p><p>** Brokerage says M&amp;A is booming (about $101B in 2025, over double compared with 2024), and big pharma still needs to buy growth, so deal activity should stay strong into early 2026</p><p>** Believes the funding environment has improved: secondary offerings and private financing are up, and 2025 IPOs have performed well, suggesting the IPO window should reopen in 2026</p><p>** Policy and pricing fears (IRA, MFN, tariffs, inflation) are proving less damaging than initially feared, though regulatory volatility will continue, says brokerage</p><p>** RBC says after the big rally, valuations are less cheap and many hot areas are crowded, so investors must be more selective</p><p>** Brokerage sees Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>KYMR.O</span>, <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> <span>APOG.O</span>, Xenon Pharmaceuticals <span>XENE.O</span> and Ascendis Pharma <span>A71.F</span> as potential takeout targets</p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026</title></head><body><p>** Brokerage RBC Capital Markets says biotech sector has strongly rebounded since April 2025, helped by good clinical data and successful new drug launches, creating more profitable, mature mid-cap names</p><p>** Brokerage says M&amp;A is booming (about $101B in 2025, over double compared with 2024), and big pharma still needs to buy growth, so deal activity should stay strong into early 2026</p><p>** Believes the funding environment has improved: secondary offerings and private financing are up, and 2025 IPOs have performed well, suggesting the IPO window should reopen in 2026</p><p>** Policy and pricing fears (IRA, MFN, tariffs, inflation) are proving less damaging than initially feared, though regulatory volatility will continue, says brokerage</p><p>** RBC says after the big rally, valuations are less cheap and many hot areas are crowded, so investors must be more selective</p><p>** Brokerage sees Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>KYMR.O</span>, <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> <span>APOG.O</span>, Xenon Pharmaceuticals <span>XENE.O</span> and Ascendis Pharma <span>A71.F</span> as potential takeout targets</p><p> (Reporting by Padmanabhan Ananthan)</p><p> ((Padmanabhan.Ananthan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0648001328.SGD","symbol_name":"Natixis Harris Associates US Equity RA SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0QE:1","article_id":"2592994926","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592994926","pubTimestamp":1765971925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026** Brokerage RBC Capital Markets says biotech sector has strongly rebounded since April 2025, helped by good ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4086":"建筑产品","BK":"纽约梅隆银行","BK4559":"巴菲特持仓","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","APOG":"Apogee Enterprises","BK4135":"资产管理与托管银行","BK4588":"碎股","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","KYMR":"Kymera Therapeutics, Inc.","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","XENE":"Xenon制药","APGE":"Apogee Therapeutics","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H"},"translate_title":"BUZZ-RBC表示生物技术行业反弹势头强劲，2026年机遇诱人","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BK":0.9,"XENE":0.9,"APGE":0.9,"KYMR":0.9,"APOG":0.9},"content_text":"BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026** Brokerage RBC Capital Markets says biotech sector has strongly rebounded since April 2025, helped by good clinical data and successful new drug launches, creating more profitable, mature mid-cap names** Brokerage says M&A is booming (about $101B in 2025, over double compared with 2024), and big pharma still needs to buy growth, so deal activity should stay strong into early 2026** Believes the funding environment has improved: secondary offerings and private financing are up, and 2025 IPOs have performed well, suggesting the IPO window should reopen in 2026** Policy and pricing fears (IRA, MFN, tariffs, inflation) are proving less damaging than initially feared, though regulatory volatility will continue, says brokerage** RBC says after the big rally, valuations are less cheap and many hot areas are crowded, so investors must be more selective** Brokerage sees Kymera Therapeutics KYMR.O, Apogee Therapeutics APOG.O, Xenon Pharmaceuticals XENE.O and Ascendis Pharma A71.F as potential takeout targets (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592994926","isCrawlerRequest":true}